New Cousteau-Linked...
Health Care: Drugs
Array BioPharma Inc. (ARRY: NASDAQ)
$3.38 -0.04 | -1.17%
06/04/12 - 04:00 PM ET
Ratio Comparisons
| Company | Industry | S&P 500 | |
| Valuation Ratios | |||
|---|---|---|---|
| P/E Ratio (TTM) | n.a. | 75.30 | 17.70 |
| P/E High - Last 5 Yrs | n.a. | n.a. | 67.70 |
| P/E Low - Last 5 Yrs | n.a. | n.a. | 12.50 |
| Beta | 1.53 | 0.58 | 0.98 |
| Price to Sales (TTM) | 3.65 | 4.62 | 1.42 |
| Price to Book (MRQ) | 0.00 | 3.44 | 2.41 |
| Price to Tangible Book (MRQ) | -3.20 | 6.74 | 5.08 |
| Price to Cash Flow (TTM) | -10.10 | 26.10 | 9.80 |
| Price to Free Cash Flow (TTM) | -7.90 | 48.80 | 17.40 |
| Dividends | |||
| Dividend Yield (%) | 0.00 | 0.50 | 2.10 |
| Dividend Yield - 5 Yr Avg (%) | n.a. | 0.20 | 2.20 |
| Dividend 5 Yr Growth Rate (%) | n.a. | n.a. | -0.76 |
| Payout Ratio (TTM) | 0.00 | 3.00 | 30.00 |
| Sales (MRQ) vs Qtr 1 Yr Ago (%) | 7.10 | 9.90 | 11.80 |
| Sales (TTM) vs TTM 1 Yr Ago (%) | 33.40 | 7.70 | 9.20 |
| Growth Rates (%) | |||
| Sales - 5 Yr Growth Rate (%) | 20.62 | 9.03 | 1.79 |
| EPS (MRQ) vs Qtr 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS (TTM) vs TTM 1 Yr Ago (%) | n.a. | 18.50 | 17.50 |
| EPS - 5 Yr Growth Rate (%) | n.a. | n.a. | -1.66 |
| Capital Spending - 5 Yr Growth Rate (%) | -27.51 | -4.13 | -1.17 |
| Financial Strength | |||
| Quick Ratio (MRQ) | 1.30 | 2.90 | 1.10 |
| Current Ratio (MRQ) | 1.40 | 3.50 | 1.60 |
| LT Debt to Equity (MRQ) | 0.00 | 0.41 | 0.82 |
| Total Debt to Equity (MRQ) | n.a. | 0.45 | 0.96 |
| Interest Coverage (TTM) | n.a. | 6.20 | 5.50 |
| Profitability Ratios (%) | |||
| Gross Margin (TTM) | 77.80 | 84.10 | 46.90 |
| Gross Margin - 5 Yr Avg | 58.70 | 83.50 | 47.70 |
| EBITD Margin (TTM) | -13.00 | 27.30 | 18.90 |
| EBITD - 5 Yr Avg | -97.34 | 0.00 | 0.00 |
| Pre-Tax Margin (TTM) | -44.70 | 14.10 | 12.10 |
| Pre-Tax Margin - 5 Yr Avg | n.a. | 10.60 | 10.30 |
| Management Effectiveness (%) | |||
| Net Profit Margin (TTM) | -0.45 | 0.10 | 0.09 |
| Net Profit Margin - 5 Yr Avg | n.a. | 5.30 | 7.00 |
| Return on Assets (TTM) | -31.10 | 4.70 | 3.10 |
| Return on Assets - 5 Yr Avg | -60.70 | 2.20 | 2.50 |
| Return on Investment (TTM) | -307.00 | 6.10 | 7.90 |
| Return on Investment - 5 Yr Avg | -280.00 | 2.80 | 6.50 |
| Efficiency | |||
| Revenue/Employee (TTM) | 322,463.00 | 701,747.00 | 449,376.00 |
| Net Income/Employee (TTM) | -144,027.00 | 83,589.00 | 39,003.00 |
| Receivable Turnover (TTM) | n.a. | 5.80 | 7.60 |
| Inventory Turnover (TTM) | n.a. | 1.30 | 8.30 |
| Asset Turnover (TTM) | 0.70 | 0.40 | 0.40 |
Portfolios with ARRY
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- Contributor7 Cancer Drug Stocks to Kno...
- ContributorStocks Under-$10 Moving Hig...
- ContributorUnder-$10 Setting Up To Tra...
- UserASCO 2010
- ContributorBarron's Activist Stocks 1-...
- UserPART 6 JPMorgan 28th Annual...
- ContributorBarron's Activist Stocks 1-...
- ContributorBarron's Activist Stocks 1-...
Latest ARRY Headlines from TheStreet
- ASCO 2012 Live Blog -- Monday 06.04.12 | 06:06 am
- Biotech Stock Mailbag: ASCO, Celldex, Obesity Drug Game-Changer 05.25.12 | 05:05 am
- The Next Big Thing in Biotech: ASCO Conference
05.25.12 | 05:05 am - 7 Stocks Under $10 Making Big Moves 05.17.12 | 12:05 pm
- Biotech Stock Live Chat Recap: ASCO & Obesity 05.17.12 | 11:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus (Update) 05.17.12 | 06:05 am
- ASCO '12 Abstract Dump: Cancer Stocks in Focus 05.16.12 | 06:05 pm
- Hot Biotech Stocks Traded by Hedge Funds in First Quarter 05.16.12 | 07:05 am
- 7 Cancer Drug Stocks to Know Right Now 03.14.12 | 09:03 am
- Array BioPharma Stock Gaps Down On Today's Open (ARRY) 02.09.12 | 08:02 am
Press Releases for ARRY
- Promising Data For KRAS Mutant Advanced NSCLC Patients Presented At ASCO - Business Wire 06.04.12 | 05:06 pm
- MEK162 Shows Promising Clinical Activity In Ongoing Phase 2 Trial - Business Wire 06.04.12 | 04:06 pm
- Array BioPharma To Present At The Jefferies 2012 Global Healthcare Conference - Business Wire 05.30.12 | 03:05 pm
- Array BioPharma And Genentech's Strategic Alliance Voted Breakthrough Alliance Of 2012 - Business Wire 05.14.12 | 06:05 pm
- Liam Ratcliffe, M.D., Ph.D., Independent Director, Array BioPharma Board Of Directors (Photo: Business Wire) - Business Wire 04.30.12 | 08:04 am
- Array BioPharma To Report Financial Results For The Third Quarter Of Fiscal 2012 On April 30, 2012 - Business Wire 04.23.12 | 04:04 pm
- Array BioPharma Names Howard Holden, Ph.D., Vice President Of Regulatory Affairs And Quality Assurance - Business Wire 04.16.12 | 08:04 am
- Encouraging Selumetinib Results Announced For Phase 2 Trial In Ovarian Cancer - Business Wire 04.04.12 | 09:04 am
- Array BioPharma To Present At The Cowen And Company 32nd Annual Health Care Conference - Business Wire 02.27.12 | 01:02 pm
- Array BioPharma Announces Closing Of Public Offering Of Common Stock And Exercise Of Overallotment Option - Business Wire 02.14.12 | 09:02 am
Partner Headlines for ARRY
- Array BioPharma Says Encouraging Selumetinib Results Announced for Phase 2 Trial in Ovarian Cancer - Benzinga 04.04.12 | 09:04 am
- Company News for February 10, 2012 - Corporate Summary - Zacks 02.10.12 | 10:02 am
- Biotech Stocks To Watch In 2012 - Seeking Alpha 02.06.12 | 09:02 am
- Array BioPharma Names Gwen A. Fyfe, M.D. to Board of Directors - Benzinga 01.30.12 | 04:01 pm
- Zacks #1 Rank Additions for Thursday - Tale of the Tape - Zacks 11.03.11 | 09:11 am
- Bottom Bounce for Array BioPharma - Seeking Alpha 06.29.11 | 09:06 am
- Future Biotech Superstars - Seeking Alpha 03.30.11 | 09:03 am
- How Array Got Its Groove Back - SeekingAlpha.com 04.28.10 | 01:04 pm
- Biotech Gets Busy With Small Company Financings - SeekingAlpha.com 04.25.10 | 08:04 am
- Array and Novartis Ink Deal - Analyst Blog - Zacks 04.22.10 | 02:04 pm
